Debt-to-equity in % of Propanc Biopharma, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Propanc Biopharma, Inc. quarterly Debt-to-equity history and change rate from Q1 2020 to Q3 2025.
  • Propanc Biopharma, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 42.7 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Propanc Biopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 42.7 +145 30 Sep 2025
Q2 2025 78.3 +182 30 Jun 2025
Q1 2025 276 +380 31 Mar 2025
Q4 2024 -102 +3.37 +3.21% 31 Dec 2024
Q3 2024 -103 +1.38 +1.33% 30 Sep 2024
Q2 2024 -104 -0.33 -0.32% 30 Jun 2024
Q1 2024 -104 -0.22 -0.21% 31 Mar 2024
Q4 2023 -105 -1.08 -1.04% 31 Dec 2023
Q3 2023 -104 -0.21 -0.2% 30 Sep 2023
Q2 2023 -103 +0.32 +0.31% 30 Jun 2023
Q1 2023 -104 -0.52 -0.5% 31 Mar 2023
Q4 2022 -104 -2 -1.96% 31 Dec 2022
Q3 2022 -104 -2.7 -2.67% 30 Sep 2022
Q2 2022 -104 -2.54 -2.51% 30 Jun 2022
Q1 2022 -103 -1.34 -1.32% 31 Mar 2022
Q4 2021 -102 -0.06 -0.06% 31 Dec 2021
Q3 2021 -101 +0.56 +0.55% 30 Sep 2021
Q2 2021 -101 +1.04 +1.02% 30 Jun 2021
Q1 2021 -102 +0.4 +0.39% 31 Mar 2021
Q4 2020 -102 31 Dec 2020
Q3 2020 -102 30 Sep 2020
Q2 2020 -102 30 Jun 2020
Q1 2020 -102 31 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.